PHC-14-2015
PHC-14-2015
10 projects · €59,342,499 total EU contribution (project-level) · 106 participating organizations · 21 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€59,342,499
Countries active
Participant organizations by country (headquarters in CORDIS).
- UK (21)
- Germany (17)
- Netherlands (13)
- France (9)
- Italy (9)
- Spain (8)
- SE (5)
- US (4)
- BE (3)
- DK (3)
- CH (2)
- CZ (2)
- NO (2)
- FI (1)
- HU (1)
- IL (1)
- LU (1)
- LV (1)
- PL (1)
- PT (1)
- RO (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- UNIVERSITY COLLEGE LONDON3 projects · UK
- Leiden University Medical Center2 projects · NL
- GENETHON2 projects · FR
- ABSISKEY1 projects · FR
- UNIVERSITAIR MEDISCH CENTRUM GRONINGEN1 projects · NL
- LEITAT1 projects · ES
- acure1 projects · SE
- CSIC1 projects · ES
- AMPHERA BV1 projects · NL
- ASPHALION1 projects · ES
- AVIDIN KFT1 projects · HU
- Azienda Ospedaliero Univesitaria Ospedali Riuniti Umberto I- G.M. Lancisi- G. Salesi1 projects · IT
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
DevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID) SCIDNET · 666908 | H2020 | €6,926,313 | €25,000 | Details |
New therapies for uveal melanoma UM Cure 2020 · 667787 | H2020 | €6,183,456 | €213,793 | Details |
INtestinal Tissue ENgineering Solution INTENS · 668294 | H2020 | €5,990,464 | €138,095 | Details |
Intra Erythrocyte Dexamethasone in the treatment of Ataxia Telangiectasia IEDAT · 667946 | H2020 | €5,871,825 | €400,000 | Details |
Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters TAT-CF · 667079 | H2020 | €4,591,288 | €610,274 | Details |
Developing new therapies for Batten disease BATCure · 666918 | H2020 | €5,995,769 | €400,000 | Details |
DC-based immunotherapy to treat Malignant Mesothelioma H2020MM04 · 668769 | H2020 | €5,782,965 | €669,216 | Details |
VISION-DMD - Phase 2 Clinical Trials of VBP15: An Innovative Steroid-like Intervention on Duchenne Muscular Dystrophy VISION DMD · 667078 | H2020 | €6,000,000 | €339,500 | Details |
Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia AML-VACCiN · 667713 | H2020 | €6,001,482 | €1,301,900 | Details |
Development of an innovative gene therapy platform to cure rare hereditary muscle disorders MYOCURE · 667751 | H2020 | €5,998,938 | €555,175 | Details |